Liquid Biopsy Technologies for Advancing Precision Oncology

Join us for an exclusive one-day virtual event covering the latest innovations in liquid biopsy and their transformative impact on cancer research and precision medicine. Liquid biopsy is a minimally invasive technique that requires highly sensitive technologies to detect low amounts of cell-free DNA (cfDNA). This online experience will showcase cutting-edge technologies for analyzing cfDNA, including circulating tumor DNA (ctDNA). Discover how researchers are applying targeted next-generation sequencing (NGS), methylation profiling, and rigorous sample quality control to accelerate progress in translational cancer research. This event is essential for anyone seeking to enhance their NGS workflows, improve data quality, and derive meaningful real-world insights from liquid biopsy samples. By attending this event, you will: Understand how liquid biopsy is revolutionizing early cancer detection and monitoring. Learn how to overcome challenges when working with cfDNA and ctDNA, such as low input volumes, degradation and high molecular weight DNA contamination. Explore sample quality control solutions optimized for liquid biopsy samples, including Agilent Cell-free DNA ScreenTape assay for TapeStation systems. Discover methylation-based techniques using high-sensitivity targeted Methyl-seq workflow, including an innovative conversation method. Explore how Agilent Avida Duo technology enables simultaneous DNA and methylation profiling from a single input sample. Gain insight into how multiomic and epigenetic analyses are shaping the future of precision oncology. For Research Use Only. Not for use in diagnostic procedures.